Mayne In Patent-Cliff Exposure & CMS Drug Spending Portfolio
Mayne In (US): 21 reconciled FDA prescription therapies, $26.0M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 21 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | 2037-01-01 |
| 2024 CMS Total Public Spend | $26.0M |
| 2024 Medicare Part D Spend | $13.6M |
| 2024 Medicaid Spend | $12.3M |
| California HCAI SB 17 Filings | 1 WAC filings (max 174.7% 2-yr change) |